Mary Hames is a distinguished leader in Medical Affairs with over a decade of cross-functional experience spanning the pharmaceutical and biotechnology industries. She has consistently driven innovation at the intersection of clinical research, genetic diagnostics, and strategic product launch. With a foundation in biochemical genetics and a PhD in Biotechnology, Mary brings a powerful blend of scientific rigor, operational excellence, and strategic foresight to every endeavor. Her track record includes building and managing high-performing medical affairs teams, driving pre- and post-launch readiness, and pioneering solutions in rare neurological diseases and radiopharmaceuticals.
Currently, Mary serves as the Founder and Head of BioLogic Pharma Solutions, a consulting firm she launched in 2024 to support pharmaceutical and biotech companies navigating complex launch landscapes. In this role, she leads a team of specialized medical, clinical, and operational consultants, offering tailored strategies to ensure clients are nimble and prepared for commercialization challenges. Her hands-on leadership style and deep industry insight have positioned her firm as a trusted partner in bringing life-changing therapies to market.
Previously, Mary held the role of US Senior Medical Director at Telix Pharmaceuticals, where she led the U.S. medical field team during a pivotal period of expansion and product launch in oncology imaging. Her leadership contributed to the execution of robust medical strategies, including investigator-initiated trial (IIT) management, congress planning, and KPI development. At BridgeBio, she played a foundational role in launching Origin Therapeutics by building and mentoring a Medical Science Liaison (MSL) team focused on a rare neonatal epilepsy. Her work included developing national preparedness metrics and leading projects related to the genetics of rare disease, all under pressing commercial timelines.
As CEO of GenetAssistant, Mary combined her scientific and operational expertise to support physicians and biopharma clients in navigating the rare disease and genetic testing landscape. Her ability to identify and enroll patients in rare disease trials earned her recognition for driving results in one of the most complex areas of medicine.
Mary’s earlier roles at Discovery Life Sciences and Ultragenyx further exemplify her leadership in diagnostics and clinical affairs. At Ultragenyx, she held dual roles as Associate Director of Laboratory and Testing Services and as Senior MSL and Genetics Lead. In these capacities, she was instrumental in aligning diagnostic programs with broader development strategies, supporting Glut1 Phase 3 trial enrollment, and curating genotype-phenotype data across global teams. Her contributions to neurogenetic education and training, particularly in Europe and the U.S., established her as a thought leader in the medical genetics community.
Mary began her industry journey with a strong academic background, completing a PhD in Biotechnology and multiple degrees in Chemistry at the University of Alabama Huntsville. She also holds an Executive MBA from Kennesaw State University, equipping her with the business acumen needed to lead in complex, matrixed environments. During her graduate career, she contributed to academic instruction in genetics and biochemistry while engaging in interdisciplinary research at the U.S. Space and Rocket Center, showcasing her passion for science communication and innovation.
Known for her strengths in coaching, field team development, and cross-functional leadership, Mary excels in aligning medical strategy with corporate goals. Her core competencies include site and trial management, congress execution, IIT strategy, diagnostic development, and launch preparedness. Whether in executive leadership or scientific consultation, Mary Hames brings integrity, precision, and a deep commitment to improving patient outcomes in rare and complex disease areas.
Character
Mary Hames demonstrates a steadfast commitment to advancing patient care in complex and underserved therapeutic areas, consistently leading with integrity, empathy, and a deep sense of purpose. Her reputation as a collaborative and values-driven leader is grounded in her dedication to mentoring teams, driving excellence, and remaining adaptable in fast-paced, high-stakes environments.
Knowledge
With a PhD in Biotechnology and a strong foundation in biochemical genetics, Mary brings a rare depth of scientific expertise to the pharmaceutical and biotech industries. Her comprehensive understanding of rare diseases, diagnostics, and clinical operations allows her to develop effective strategies that bridge scientific innovation with real-world impact.
Strategic
Mary excels in designing and executing high-level strategies for medical affairs, clinical development, and product launches, especially in the rare disease and oncology sectors. Her ability to build and lead nimble teams, optimize trial recruitment, and align cross-functional goals positions her as a trusted advisor and transformative leader across the drug development lifecycle.
Communication
Mary is a skilled communicator who fosters strong relationships with internal stakeholders, healthcare professionals, and key opinion leaders alike. Whether developing training programs, leading congress initiatives, or collaborating with global teams, she brings clarity, precision, and influence to every interaction.
